---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-249348"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:19:24.559315+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology receives $30M milestone from Kyowa Kirin for first patient dosed in Phase 3 ziftomenib trial

## Summary
- $30M milestone payment triggered by first patient dosed in KOMET-017 Phase 3 registrational trials.
- Trials evaluate ziftomenib in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.
- KOMET-017 consists of two global, randomized, double-blind, placebo-controlled Phase 3 studies.
- Payment received under Collaboration and License Agreement with Kyowa Kirin.

## SEC filing metadata
- accession: 0001193125-25-249348
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312525249348/0001193125-25-249348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312525249348/d939392d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-249348
- JSON: https://secwatch.observer/filing/0001193125-25-249348.json
- Plain text: https://secwatch.observer/filing/0001193125-25-249348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.